INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughput<i>in vivo</i> testing

Marcel Kool(German Cancer Research Center), Aniello Federico(German Cancer Research Center), Didier Surdez(Inserm), Apurva Gopisetty(German Cancer Research Center), Elnaz Saberi-Ansari(Inserm), Alexandra Saint‐Charles(Inserm), Yasmine Iddir(Inserm), Joshua J. Waterfall(Inserm), Justyna A. Wierzbińska(Bayer (Germany)), Andreas Schlicker(Bayer (Germany)), Jaydutt Bhalsankar(Inserm), Norman Mack(German Cancer Research Center), Benjamin Schwalm(German Cancer Research Center), Anna-Lisa Böttcher(German Cancer Research Center), Martin Sill(German Cancer Research Center), Frank Westermann(German Cancer Research Center), David Jones(German Cancer Research Center), Richard Volckmann, Danny A. Zwijnenburg, Dennis Gürgen, Emilie Inderise, Johannes H. Schulte(Charité - Universitätsmedizin Berlin), Angelika Eggert, Jan J. Molenaar(Princess Máxima Center), Olivier Delattre(Inserm), Sara Colombetti(Roche (Switzerland)), Olaf Heidenreich(Princess Máxima Center), Irmela Jeremias(Helmholtz Zentrum München), Katia Scotlandi(Istituto Ortopedico Rizzoli), Maria Cristina Manara(Istituto Ortopedico Rizzoli), Johannes Gojo(German Cancer Research Center), Walter Berger, Fátima Iradier(Eli Lilly (United States)), Birgit Geoerger(Institut Gustave Roussy), Jenny Costa(Institut Gustave Roussy), Beat W. Schäfer(University Children's Hospital Zurich), Marco Wachtel(University Children's Hospital Zurich), Louis Chesler(Institute of Cancer Research), Chris Jones(Institute of Cancer Research), Heinrich Kovar(St Anna Children's Hospital), Ángel M. Carcaboso(Institut de Recerca Sant Joan de Déu), Jan‐Henning Klusmann(Martin Luther University Halle-Wittenberg), Klaus‐Michael Debatin(Universität Ulm), Simon Bomken(Great North Children's Hospital), Christina Guttke(Janssen (United States)), Petra Hamerlik(AstraZeneca (United Kingdom)), Maureen M. Hattersley(AstraZeneca (United States)), Michelle Garcia(Amgen (United States)), Frédéric Colland(Servier (France)), Ashley Strougo(Sanofi (Germany)), Olaf Witt(German Cancer Research Center), Gilles Vassal(Institut Gustave Roussy), Hubert Caron(Roche (Switzerland)), David J. Shields(Pfizer (United States)), Lou F. Stancato(Eli Lilly (United States)), Pablo M Aviles(Institut de Recerca Sant Joan de Déu), Jens Hoffmann, Stefano Cairo, Julia Schüler(Charles River Laboratories (Germany)), Natalie Jäger(German Cancer Research Center), Jan Köster, Gudrun Schleiermacher(Inserm), Stefan M. Pfister(German Cancer Research Center)
Neuro-Oncology
June 1, 2022
Cited by 2Open Access
Full Text

Abstract

Abstract Thanks to state-of-the-art molecular profiling techniques we by now have a much better understanding of pediatric cancers and what is driving them. On the other hand, we have also realized that pediatric cancers are much more heterogeneous than previously thought. Many new types and subtypes of pediatric cancers have been identified with distinct molecular and clinical characteristics. However, for many if not most of these new types and subtypes there is no specific treatment available, yet. In order to develop specific treatment protocols and to increase survival rates for pediatric cancer patients further, both at diagnosis and relapse/metastasis, we need a large collection of well-characterized preclinical models representing all the different types and subtypes. These models can be used for preclinical drug testing to prioritize the pediatric development of anticancer drugs that would be best targeting pediatric tumor biology. The ITCC-P4 consortium, which is a collaboration between many academic centers across Europe, several companies involved in in vivo preclinical testing, and ten pharmaceutical companies, started in 2017 with the overall aim to establish a sustainable platform of &amp;gt;400 molecularly well-characterized PDX models of high-risk pediatric cancers and to use them for in vivo testing of novel mechanism-of-action based treatments. Currently, 340 models have been fully established, including 87 brain tumor models and 253 non-brain tumor models, together representing many different tumor types both from primary and relapsed/metastatic disease. Out of these 340 models, 252 have been fully molecularly characterized, most of them together with their matching original tumors, and almost of all these models are currently being subjected to in vivo testing using three standard of care drugs and six novel mechanism-of-action based drugs. In this presentation, an update on the current status of the ITCC-P4 platform and the data we collectively have generated thus far will be presented.


Related Papers

No related papers found

Powered by citation graph analysis